EIB gives EUR 20 million loan to anaesthesia and sedation drugs company
The Aachen-based company is currently developing remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for use in procedural sedation, general anaesthesia and intensive care unit (ICU) sedation.
The EU bank’s loan will support PAION’s R&D investment programme to bring remimazolam to market.
The loan is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the heart of the Investment Plan for Europe the Juncker Plan under which the EIB and the European Commission are working together as strategic partners and the EIB’s financing operations are boosting the competitiveness of the European economy. ■